Back to trial detailsIntake questionnaire
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Applying to Winship Cancer Institute of Emory University · Atlanta, Georgia
Answer a few short questions to share with the research team.
0 of 4 answered